human amniotic epithelium-derived stem cells (Icell Biotechnology/The Second Affiliated Hospital of Chongqing Medical University)

N/A

Report date: 2026/02/24 20:00:16

Base Information

Drug Namehuman amniotic epithelium-derived stem cells (Icell Biotechnology/The Second Affiliated Hospital of Chongqing Medical University)
Drug Alias Namehuman amniotic epithelium-derived stem cells (Icell Biotechnology/The Second Affiliated Hospital of Chongqing Medical University)hAESCs (Icell Biotechnology/The Second Affiliated Hospital of Chongqing Medical University)hAECs-dervied stem cells (Icell Biotechnology/The Second Affiliated Hospital of Chongqing Medical University)stem cell therapy (Icell/Chongqing Medical University)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Epithelial stem cell therapy
Mechanisms of ActionStem cells modulators
TargetsUpdating
Therapy Area/IndicationsGraft vs Host DiseaseUterine DiseasesPrimary Ovarian Insufficiency +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Icell Biotechnology Co., Ltd, Shanghai, China
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Icell Biotechnology Co., Ltd, Shanghai, ChinaThe Second Affiliated Hospital Of Chongqing Medical University
Inactive CompaniesN/A
Active IndicationsGraft vs Host DiseaseUterine DiseasesPrimary Ovarian Insufficiency +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A